Of the three FDA-approved predictive biomarker tests for anti-PD-(L)1 immunotherapy, PD-L1 assessed in tumor tissues by immunohistochemistry (IHC) is the most commonly used biomarker for patient stratification [15,16]. Here, CD274 is linked to neoplasm.